Zoetis Inc. reported third-quarter 2024 revenue of $2.4 billion, an 11% increase compared to Q3 2023, and a 14% increase on an operational basis. Adjusted net income reached $716 million, or $1.58 per diluted share, representing a 14% reported increase and a 15% operational increase.
The company's companion animal portfolio grew 15% operationally, with the OA pain mAbs franchise (Librela and Solensia) contributing $151 million, a 97% operational growth. The Simparica franchise grew 27% operationally to $333 million, and the Key Dermatology franchise grew 16% operationally to $449 million.
Zoetis raised its full-year 2024 guidance, now projecting revenue between $9.20 billion and $9.30 billion, up from the prior range of $9.10 billion to $9.25 billion. Adjusted diluted EPS is expected to be between $5.86 and $5.92, an increase from the previous forecast of $5.78 to $5.88.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.